Publications
Multiscale adaptive generalized estimating equations for longitudinal neuroimaging data." Neuroimage 72 (2013): 91-105.
"Multiscale adaptive marginal analysis of longitudinal neuroimaging data with time-varying covariates." Biometrics 68, no. 4 (2012): 1083-92.
"Multiscale Adaptive Regression Models for Neuroimaging Data." J R Stat Soc Series B Stat Methodol 73, no. 4 (2011): 559-578.
"Multisensory Logic of Infant-Directed Aggression by Males." Cell 175, no. 7 (2018): 1827-1841.e17.
"A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression." Stat Biopharm Res 8, no. 1 (2016): 12-21.
" Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life." PLoS One 9, no. 9 (2014): e108306.
"Multivariate network-level approach to detect interactions between large-scale functional systems." Med Image Comput Comput Assist Interv 13, no. Pt 2 (2010): 298-305.
"Multivariate phenotype association analysis by marker-set kernel machine regression." Genet Epidemiol 36, no. 7 (2012): 686-95.
"Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42.
"MULTIVARIATE VARYING COEFFICIENT MODEL FOR FUNCTIONAL RESPONSES." Ann Stat 40, no. 5 (2012): 2634-2666.
"Multivariate varying coefficient models for DTI tract statistics." Med Image Comput Comput Assist Interv 13, no. Pt 1 (2010): 690-7.
"Network Meta-analysis for Ordinal Outcomes: Applications in Comparing Crohn's Disease Treatments., 2016.
Network meta-analysis of margin threshold for women with ductal carcinoma in situ." J Natl Cancer Inst 104, no. 7 (2012): 507-16.
"Network meta-analysis of randomized clinical trials: reporting the proper summaries." Clin Trials 11, no. 2 (2014): 246-62.
"Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments." Stat Med (2020).
"A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials." Stat Med 38, no. 30 (2019): 5565-5586.
"A New Method for Detecting Associations with Rare Copy-Number Variants." PLoS Genet 11, no. 10 (2015): e1005403.
"A New Monte Carlo Method for Estimating Marginal Likelihoods." Bayesian Anal 13, no. 2 (2018): 311-333.
"New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes." J Am Stat Assoc 110, no. 510 (2015): 583-598.
"Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
"Nomenclature for alleles of the thiopurine methyltransferase gene." Pharmacogenet Genomics 23, no. 4 (2013): 242-8.
"Nonconvex Optimization. In Wiley StatsRef: Statistics Reference Online., 2018.
Noncrossing quantile regression curve estimation." Biometrika 97, no. 4 (2010): 825-838.
"Nonparametric estimation of the mean function for recurrent event data with missing event category." Biometrika 100, no. 3 (2013).
"A nonparametric spatial model for periodontal data with non-random missingness." J Am Stat Assoc 108, no. 503 (2013).
" normDesign: Bayesian sample size for non-inferiority randomized trials with normal data (SAS).., 2016.
A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events." Pharm Stat 14, no. 4 (2015): 273-83.
"Nucleotide excision repair capacity increases during differentiation of human embryonic carcinoma cells into neurons and muscle cells." J Biol Chem 294, no. 15 (2019): 5914-5922.
"Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications." Genome Biol 19, no. 1 (2018): 24.
"odsroc: Nonparametric estimation of AUC and partial AUC under test-result-dependent sampling (R).., 2012.
Online updating method with new variables for big data streams." Can J Stat 46, no. 1 (2018): 123-146.
"Online Updating of Statistical Inference in the Big Data Setting." Technometrics 58, no. 3 (2016): 393-403.
"Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data." BMC Med Res Methodol 16, no. 1 (2016): 122.
"Optimal dynamic treatment regimes In Wiley Statsref. Optimal dynamic treatment regimes., 2016.
Optimal estimation for regression models on τ-year survival probability." J Biopharm Stat 25, no. 3 (2015): 539-47.
"The optimal power puzzle: scrutiny of the monotone likelihood ratio assumption in multiple testing." Biometrika 100, no. 2 (2013): 495-502.
"Optimal treatment allocations in space and time for on-line control of an emerging infectious disease." J R Stat Soc Ser C Appl Stat 67, no. 4 (2018): 743-770.
"Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective." Lifetime Data Anal 23, no. 4 (2017): 585-604.
"On optimal treatment regimes selection for mean survival time." Stat Med 34, no. 7 (2015): 1169-84.
" Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.
"Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART." Contemp Clin Trials 57 (2017): 51-57.
"OTRselect: Variable selection for optimal treatment decision (R).. 1.0 ed. CRAN Repository, 2016.
Outcome-Dependent Sampling Design and Inference for Cox's Proportional Hazards Model." J Stat Plan Inference 178 (2016): 24-36.
"Outcome-dependent sampling with interval-censored failure time data." Biometrics 74, no. 1 (2018): 58-67.
" Parameter estimation in Cox models with missing failure indicators and the OPPERA study." Stat Med 34, no. 30 (2015): 3984-96.
"Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation." Biometrics 70, no. 3 (2014): 765-73.
"Partial likelihood estimation of isotonic proportional hazards models." Biometrika 105, no. 1 (2018): 133-148.
"Partition Weighted Approach for Estimating the Marginal Posterior Density with Applications." J Comput Graph Stat 28, no. 2 (2019): 334-349.
"Pathway-based identification of SNPs predictive of survival." Eur J Hum Genet 19, no. 6 (2011): 704-9.
"Pathway-guided identification of gene-gene interactions." Ann Hum Genet 78, no. 6 (2014): 478-91.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
" A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies." Biometrics 71, no. 2 (2015): 529-37.
"Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics 73, no. 4 (2017): 1343-1354.
"Penalized Q-Learning for Dynamic Treatment Regimens." Stat Sin 25, no. 3 (2015): 901-920.
" Performance of rapid influenza H1N1 diagnostic tests: a meta-analysis." Influenza Other Respir Viruses 6, no. 2 (2012): 80-6.
"permGPU: Using graphics processing units in RNA microarray association studies." BMC Bioinformatics 11 (2010): 329.
" Personalized Dose Finding Using Outcome Weighted Learning." J Am Stat Assoc 111, no. 516 (2016): 1509-1521.
"Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective." Stat Biosci 8, no. 1 (2016): 43-65.
"PERTURBATION AND SCALED COOK'S DISTANCE." Ann Stat 40, no. 2 (2012): 785-811.
" Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
"Pharmacogenomic interrogation of colorectal cancer using next-generation whole exome sequencing., 2011.
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint." Med Res Arch 5, no. 7 (2017).
" PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med 8, no. 369 (2016): 369ra175.
"POINT: Protein Structure Guided Local Test (R). 1.0 ed., 2019.
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"Posterior Contraction Rates of the Phylogenetic Indian Buffet Processes." Bayesian Anal 11, no. 2 (2016): 477-497.
"Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
" Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
"Power calculations and confidence intervals in phase II design with over enrollment (SAS/R).., 2014.
The power prior: theory and applications." Stat Med 34, no. 28 (2015): 3724-49.
"A Powerful Test for SNP Effects on Multivariate Binary Outcomes using Kernel Machine Regression." Stat Biosci 10, no. 1 (2018): 117-138.
"A practical Bayesian adaptive design incorporating data from historical controls." Stat Med 37, no. 27 (2018): 4054-4070.
"Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66.
"Precision Medicine." Annu Rev Stat Appl 6 (2019): 263-286.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Prediction of a time-to-event trait using genome wide SNP data." BMC Bioinformatics 14 (2013): 58.
"Prediction of cancer drug sensitivity using high-dimensional omic features." Biostatistics 18, no. 1 (2017): 1-14.
"